ResearchMoz

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014

Global Markets Direct
Published Date » 2014-02-28
No. Of Pages » 263
 Global Markets Direct’s, ‘Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer’s therapeutic pipeline. 
   
 This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic...
Table of Content

Introduction
Global Markets Direct Report Coverage
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
Genentech, Inc.
Bavarian Nordic A/S
Emergent BioSolutions Inc.
Takeda Pharmaceutical Company Limited
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
GTx, Inc.
Teva Pharmaceutical Industries Limited
Progenics Pharmaceuticals, Inc.
Exelixis, Inc.
Onyx Pharmaceuticals, Inc.
Merck KGaA
Active Biotech AB
Oncolytics Biotech Inc.
Oncothyreon Inc.
Medivation, Inc.
Synta Pharmaceuticals Corp.
Supratek Pharma Inc.
CellCentric Ltd.
CureVac GmbH
GenSpera, Inc.
Bind Therapeutics, Inc.
NewLink Genetics Corporation
Bellicum Pharmaceuticals, Inc.
Bostwick Laboratories, Inc.
ATLAB Pharma SAS
DexTech Medical AB
AbbVie Inc.
Sotio a.s.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
enzalutamide - Drug Profile
orteronel - Drug Profile
custirsen sodium - Drug Profile
tasquinimod - Drug Profile
enzalutamide - Drug Profile
cabozantinib (s)-malate - Drug Profile
Prostvac - Drug Profile
DCVAC/PCa - Drug Profile
patupilone - Drug Profile
DI-17-E-6 - Drug Profile
olaratumab - Drug Profile
navitoclax - Drug Profile
vandetanib - Drug Profile
PSMA ADC - Drug Profile
GTx-758 - Drug Profile
linsitinib - Drug Profile
olaparib - Drug Profile
panobinostat - Drug Profile
carfilzomib - Drug Profile
ganetespib - Drug Profile
pelareorep - Drug Profile
PX-866 - Drug Profile
CV-9103 - Drug Profile
G-202 - Drug Profile
docetaxel targeted nanoparticles - Drug Profile
buparlisib hydrochloride - Drug Profile
NLG-8189 - Drug Profile
Adenovirus/PSA Vaccine - Drug Profile
TL-118 - Drug Profile
CV-9104 - Drug Profile
Dendritic Cell Vaccine + [docetaxel] - Drug Profile
ATL-101 - Drug Profile
Anti-PSMA Designer T Cells - Drug Profile
CreaVax-PC - Drug Profile
VDC-2008 - Drug Profile
BPX-101 - Drug Profile
CFG-920 - Drug Profile
Osteodex - Drug Profile
CVA-21 - Drug Profile
RG-7450 - Drug Profile
BPX-201 - Drug Profile
ONC-1-13B - Drug Profile
ES-414 - Drug Profile
Deubiquitinase Program - Drug Profile
cabazitaxel nanoformulation - Drug Profile
Compound 54 - Drug Profile
Cannabinoid Receptors Agonists - Drug Profile
ABS-001 - Drug Profile
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables


Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Exelixis, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Active Biotech AB, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncothyreon Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GenSpera, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bind Therapeutics, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bostwick Laboratories, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H1 2014

List of Figures


Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Upcoming Reports:

Medical Plastics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Increasing need for medical devices with high shelf life, increasing export and import of medical devices, increasing demand for sterilized and disposable devices are some of the factors driving the sales of medical plastics market. Increasing demand for cost effective, light weight, the increasing use of prosthetics and the increasing use of non magnetic equipments around heavily magnetized medical equipments such as an MRI, are other factors serving as market drivers for the medical plastics market.  The rising economies in the Asia Pacific region, the rising demand for high...
Greece: cigarettes market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the cigarettes market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the cigarettes market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
DPCR Instrumentation And Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Digital PCR (dPCR) is a refinement of conventional PCR method which is primarily used to directly quantify and clonally amplify nucleic acids. The key difference between the dPCR and traditional PCR lies in the method or technique the nucleic acid amount is measured. PCR carries out one reaction per single sample whereas dPCR separates the samples into large number of partitions and then performs the reaction in each of the partitions individually. Among researchers dPCR method is found to be effective alternative for studying variations in gene sequences such as point mutation, copy...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Open to Hiring Malaysia Airlines Retrenched Employees : AirAsia CEO
Sep 11, 2014  
After reports that Malaysia Airlines will be letting go nearly 6,000 of its staff, chief executive officer of low-cost carrier AirAsia Tan Sri Tony Fernandes has said that he is open to hiring MAS ex-employees as part of its own workforce.  Fernandes said that he welcomes the MAS overhaul and the transition will be a good move for the AirAsia group as well as Malaysia Airlines....
Statoil Expands Natural Gas in Bakken
Sep 11, 2014  
A Norway-based oil company, Statoil known for dealing in natural gas has stamped its strong presence in Bakken, North Dakota. In the last three years, emissions from burning, flaring of methane, natural gas, and hydrogen sulphide related with oil production have risen tremendously. Statoil operates in the effort to expand the technology to power equipment with natural gas that would otherwise...
Apple Watch - The Latest Product Launched By Apple Inc
Sep 11, 2014  
The sale of large screen phones may witness a boost due to the additional feature of mobile payment service that has been included in Apple Inc’s latest iPhone. This could restore the market share of Apple Inc that was lost to Google Inc’s Android segment. Soon after the launch of the Apple Watch and iPhone 6, the shares of Apple rose by almost 1.3% on Wednesday. This also...
China and Russia to Hike Reciprocal Investments
Sep 10, 2014  
In a joint effort to develop high-speed rail, energy, telecommunications, housing, infrastructure projects, and mining, China and Russia have both agreed to increase their reciprocal investment. Zhang Gaoli, the Chinese Vice Premier and Igor Shuvalov, the First Deputy Prime Minister of Russia co-chaired the initial meeting of the Investment Cooperation Committee of China-Russia. The...
Asian Stocks Observe Decline amid Fed Anxiety
Sep 10, 2014  
Asian shares observed a steep decline on Wednesday amid fears that the Federal Reserve would increase interest rates earlier than expected, leading the dollar to jump to its 14-months high against major currencies. Some regional tech shares observed a hit after stocks of Apple Inc fell as the initial excitement about the launch of new products evaporated quickly. Japan stock...